Policy / Pricing 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar) Drug ChannelsJoin Dr.Read full story pharminent May 12, 2026 (Last updated: May 12, 2026) Drug Channels Join Dr. Read full story Post navigation Previous: Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosisNext: BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial Related Stories Policy / Pricing Mid-cap biotechs join Trump’s latest round of drug pricing deals pharminent September 1, 2026 Policy / Pricing MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones pharminent August 27, 2026 Policy / Pricing MFN affecting Swiss medicines access, says Interpharma pharminent August 13, 2026